Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …
been available for a long time. Therefore, conventional chemotherapy is still considered the …
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
A Tutt, H Tovey, MCU Cheang, S Kernaghan… - Nature medicine, 2018 - nature.com
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
Abstract Purpose: BRCA1/2-mutated and some sporadic triple-negative breast cancers
(TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics …
(TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics …
PARP inhibitors in the management of breast cancer: current data and future prospects
L Livraghi, JE Garber - BMC medicine, 2015 - Springer
Abstract Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study
Objectives Physical inactivity and sedentary behaviour are associated with higher breast
cancer risk in observational studies, but ascribing causality is difficult. Mendelian …
cancer risk in observational studies, but ascribing causality is difficult. Mendelian …
[HTML][HTML] CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
Background: Homologous recombination deficiency (HRD) is a common molecular
characteristic of genomic instability, and has been proven to be a biomarker for target …
characteristic of genomic instability, and has been proven to be a biomarker for target …
The role of taxanes in triple-negative breast cancer: literature review
G Mustacchi, M De Laurentiis - Drug design, development and …, 2015 - Taylor & Francis
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are
characterized by the negative estrogen and progesterone receptors and negative HER2 …
characterized by the negative estrogen and progesterone receptors and negative HER2 …
Comparison of neoadjuvant nab-paclitaxel+ carboplatin vs nab-paclitaxel+ gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results
O Gluz, U Nitz, C Liedtke, M Christgen… - JNCI: Journal of the …, 2018 - academic.oup.com
Background Pathological complete response (pCR) is associated with improved prognosis
in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear …
in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear …
[HTML][HTML] Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and …
Background Homologous recombination deficiency (HRD)-causing alterations have been
reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD …
reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD …